Product Overview
[Drug Name]
Generic Name: Flunarizine Hydrochloride Capsules
Trade Name: Qinnuoningkang
English Name: Flunarizine Hydrochloride Capsules
Chinese Pinyin: Flunarizine Hydrochloride Capsules
[Ingredients]
Flunarizine Hydrochloride
Chemical Name: (E)-1-[Bis(4-fluorophenyl)methyl]-4-(2-propenyl-3-phenyl)-piperazine dihydrochloride
Molecular Formula: C₂₆H₂₆F₂N₂₂ HCl
Molecular Weight: 477.42
[Properties]
This product is a capsule containing a white powder.
[Indications]
1. Insufficient cerebral blood supply, vertebral artery ischemia, and post-cerebral thrombosis;
2. Tinnitus and dizziness;
3. Prevention of migraines;
4. Adjunctive treatment for epilepsy.
[Dosage and Administration]
1. Preventive treatment of migraines. Starting dose: Patients under 65 years of age can begin treatment with 10 mg per night; patients over 65 years of age can begin treatment with 5 mg per night. Maintenance therapy: If the therapeutic effect is satisfactory and the patient requires maintenance therapy, the dose should be reduced to five days per week (dose as above).
2. Dizziness: The daily dose should remain the same as above, but the drug should be discontinued promptly after symptoms are controlled. The initial course of treatment is usually less than two months.
[Adverse Reactions]
1. The most common adverse reactions (often transient) are drowsiness and/or fatigue (20%). Some patients may also experience weight gain (and/or increased appetite) (11%).
2. The following serious adverse reactions (occurring in long-term users) are occasionally reported: depression, which is more common in women with a history of depression. Extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, oral and mandibular dyskinesia, tremor, etc.) are more common in the elderly.
3. Rare adverse reactions have been reported: Gastrointestinal reactions: heartburn, nausea, stomach pain. Central nervous system effects: insomnia, anxiety.
4. Other: galactorrhea, dry mouth, muscle pain, and rash.
[Contraindications]
1. This drug is contraindicated in patients with a history of allergy or depression. It is contraindicated in patients with acute cerebral hemorrhage.
2. Use with caution in children.
3. Not suitable for pregnant or breastfeeding women.
[Precautions]
1. If fatigue symptoms gradually worsen after use, the dosage should be reduced or discontinued.
2. Strictly control the dosage. If the maintenance dose is ineffective or extrapyramidal symptoms develop after long-term use, the dosage should be reduced or discontinued.
3. This drug should be used with caution in patients with extrapyramidal diseases such as Parkinson's disease.
4. Because this drug is secreted in breast milk, although there are no studies reporting teratogenicity or effects on embryonic development, it is generally not recommended for pregnant or breastfeeding women.
5. Drivers and machine operators should use with caution to avoid accidents.
[Special Use]
Precautions for Children:
Use with caution in children.
Precautions for Pregnancy and Lactation:
Not suitable for pregnant or breastfeeding women.
Precautions for Elderly Patients:
Due to the more sensitive nervous systems and reduced metabolic capacity of elderly patients, the dosage should be reduced as appropriate.
[Drug Interactions]
This product may cause excessive sedation when used with alcohol, hypnotics, or sedatives. This product is not contraindicated in patients taking beta-blockers.
[Pharmacological Actions]
Flunarizine hydrochloride is a selective calcium antagonist that blocks the entry of excessive calcium ions across cell membranes, preventing excessive intracellular calcium overload. It also prevents excessive calcium entry into neurons during ischemia and hypoxia, improving cerebral microcirculation and neuronal metabolism, inhibiting cerebral vasospasm, platelet aggregation, and increased blood viscosity. It also has a cell membrane stabilizing effect. This product is highly lipid-soluble and readily crosses the blood-brain barrier. It has no effect on cardiac contraction or conduction.
[Storage] Store in a sealed container away from light.
[Specification] 5mg x 60 tablets
[Packaging] Box
[Expiration Period] 36 months
[Approval Number] National Medicine Standard H20103601
[Manufacturer] Company Name: Shaanxi Yishengtang Pharmaceutical Co., Ltd.
